ABAlina A. Brichagina Brichagina

Alina A. Brichagina Brichagina

*This is an algorithmically generated author record based on publicly available information.

Alina A. Brichagina Brichagina has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    optogenetic tissue-engineered cardiac pacemaker: demonstration of principle in an isolated rat heart

    by Vitalii D. Dzhabrailov Dzhabrailov, Alina A. Brichagina Brichagina, Daria V. Kononova Kononova, Elena A. Turchaninova Turchaninova, Mihail M. Slotvitsky Slotvitsky, Valeriya A. Tsvelaya Tsvelaya, Konstantin I. Agladze Agladze, Alexander B. Romanov Romanov, Валерия Александровна Цвелая

    Background: Heart rhythm disturbances remain a serious problem in modern cardiology. Traditional pacemakers have certain limitations including invasiveness, risk of infection, mechanical complications, and a limited service life. Advances in bioengineering and optogenetics technologies offers new prospects for the production of minimally invasive, biocompatible, and controllable cardiac pacing systems. The combination of cell therapy and optogenetics enables to create a photo-controlled biological pacemaker, free from the key drawbacks of traditional devices. Objective: The aim of this study was to produce photosensitive cellular patches and to further investigate their functionality as an optogenetic tissue-engineered pacemaker in an ex vivo rat heart model. Methods: We engineered a cell-based construct using either human cardiomyocytes derived from induced pluripotent stem cells or neonatal rat cardiomyocytes expressing channelrhodopsin-2. These cells were seeded onto fibrous scaffolds made of poly-L-lactic acid and collagen, coated with fibronectin. The testing model was an isolated, temporarily maintained ex vivo rat heart. Optical mapping of calcium activity was used to record cardiac electrophysiology. Results: Functional coupling between the implanted patch and the host myocardium was observed 35 minutes after implantation. Photostimulation reliably increased the heart rate, which was confirmed by stochastic dominance analysis. The experiments in vitro on cell cultures demonstrated the operational capacity of channelrhodopsin-2 upon illumination with 470 nm light. Conclusion: This study successfully demonstrates a complete technology cycle, from the genetic modification of cells to the control of contractions in a whole organ. It represents a significant step towards developing targeted and safe methods for future temporary cardiac pacing. Our results confirm the fundamental feasibility of a hybrid optogenetic approach and lay the groundwork for further research into creating safe, controllable, and biocompatible next-generation pacemaker systems.

  • Open Access

    Survival of the heart in different cardioplegic solution delivery systems under extracorporeal normothermic perfusion conditions

    by S.D. Robustova, V.S. Kachan, D.V. Kononova, A.S. Yarovoy, M.A. Gusev, V.V. Litvinenko, V.D. Dzhabrailov, A.A. Brichagina, Z.V. Obrazumova, S.D. Chekalina, et al.

    Introduction: Preservation of isolated hearts in cardioplegic solution at normothermia is a promising strategy for increasing the organ lifespan. Further development of this strategy and search for new products for solution delivery can help optimize the technology of donor heart transportation. Objective: The study was aimed to test the efficacy of device for normothermic constant perfusion flow with innovative lines for the cardioplegic solution delivery (CardioSystemPharma, Khimki, Moscow Region, Russia) according to the Langendorff mode in comparison with a system based on nodes and tubes of Radnoti Langendorff Constant Perfusion Flow Apparatus (ADInstruments, Colorado Springs, USA) in a series of experiments on rat hearts.Methods: The innovative cardioplegic delivery system (CardioSystemPharma) and traditional perfusion system (Radnoti) were compared in experiments on rat hearts at normothermia without cardioplegic solution and using the cardioplegic solution Normacor (Mosfarm, Moscow Region, Russia). The time until complete cardiac arrest and the changes in the NADH coenzyme fluorescence were recorded. After cardiac arrest, immunohistochemical staining of ventricular sections was performed to detect myocardial injury during perfusion.Results: It was shown that the innovative cardioplegic delivery system was not inferior to the traditional perfusion system (Radnoti) and even surpassed it in terms of the time duration for preservation of the isolated heart. It was found that the using of elevated glucose concentration during normothermic perfusion could significantly increase the organ lifespan. The efficacy of normothermic perfusion in the experiment was confirmed by monitoring cellular respiration through recording the NADH fluorescence.Conclusion: Testing showed that long-term preservation under normothermia with usage of an innovative delivery system of Russian manufacture is a promising replacement for Radnoti solution delivery system. Received 16 October 2024. Revised 23 November 2024. Accepted 10 December 2024. FundingThe study was carried out within the framework of the project “Innovative cardioplegic lines for cardiac surgery” under the Agreement on the provision of a grant from the Government of the Moscow Region in the fields of science, technology, engineering and innovation No. 12/04-24 dated 04/27/2024. Conflict of interestThe authors declare no conflict of interest. Contribution of the authorsConception and study design: V.A. Tsvelaya, S.D. Robustova, V.S. Kachan, M.S. Nosov, A.K. Berezhnoy, V.A. Kozlov, K.I. AgladzeData collection and analysis: S.D. Robustova, V.S. Kachan, D.V. Kononova, A.S. Yarovoy, M.A. Gusev, V.V. Litvinenko, V.D. Dzhabrailov, A.A. Brichagina, Z.V. Obrazumova, S.D. Chekalina, S.S. Bakumenko, E.A. Turchaninova, V.A. TsvelayaStatistic analysis: S.D. Robustova, V.S. Kachan, D.V. Kononova, A.S. Yarovoy, M.A. Gusev, V.V. Litvinenko, V.D. Dzhabrailov, A.A. Brichagina, Z.V. Obrazumova, S.D. Chekalina, S.S. Bakumenko, E.A. TurchaninovaDrafting the article: S.D. Robustova, V.S. Kachan, D.V. Kononova, Z.V. Obrazumova, E.A. Turchaninova, V.A. TsvelayaCritical revision of the article: S.D. Robustova, E.A. Turchaninova, V.A. Tsvelaya, K.I. AgladzeFinal approval of the version to be published: S.D. Robustova, V.S. Kachan, D.V. Kononova, A.S. Yarovoy, M.A. Gusev, V.V. Litvinenko, V.D. Dzhabrailov, A.A. Brichagina, Z.V. Obrazumova, S.D. Chekalina, E.A. Turchaninova, S.S. Bakumenko, M.S. Nosov, A.K. Berezhnoy, V.A. Kozlov, V.A. Tsvelaya, K.I. Agladze